Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Crispr Therapeutics Ag (CRSP)
Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,955,539
  • Shares Outstanding, K 78,935
  • Annual Sales, $ 1,200 K
  • Annual Income, $ -650,180 K
  • 60-Month Beta 1.66
  • Price/Sales 4,255.11
  • Price/Cash Flow N/A
  • Price/Book 2.68
Trade CRSP with:

Options Overview Details

View History
  • Implied Volatility 54.70% ( -6.68%)
  • Historical Volatility 61.29%
  • IV Percentile 2%
  • IV Rank 10.07%
  • IV High 95.18% on 06/13/22
  • IV Low 50.17% on 05/04/23
  • Put/Call Vol Ratio 1.59
  • Today's Volume 3,370
  • Volume Avg (30-Day) 6,611
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 90,215
  • Open Int (30-Day) 75,468

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -2.18
  • Number of Estimates 11
  • High Estimate -2.04
  • Low Estimate -2.39
  • Prior Year -2.40
  • Growth Rate Est. (year over year) +9.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.72 +12.33%
on 05/09/23
72.00 -13.07%
on 05/23/23
+6.63 (+11.85%)
since 05/08/23
3-Month
42.00 +49.02%
on 03/24/23
72.00 -13.07%
on 05/23/23
+14.66 (+30.59%)
since 03/08/23
52-Week
38.94 +60.73%
on 12/30/22
86.95 -28.02%
on 07/20/22
-11.24 (-15.22%)
since 06/08/22

Most Recent Stories

More News
Can This Gene-Editing Stock Deliver 10X Returns?

Buying shares of Intellia Therapeutics might be a smart move.

CRSP : 62.59 (-0.30%)
NTLA : 43.36 (-0.23%)
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Today, CRISPR has reached an important turning point.

VRTX : 332.58 (+2.44%)
CRSP : 62.59 (-0.30%)
3 Top Healthcare Stocks to Buy for June

These stocks have what it takes to deliver long-term growth.

VRTX : 332.58 (+2.44%)
TMDI : 0.1400 (-26.32%)
ISRG : 310.82 (+1.17%)
DOCS : 31.93 (-2.24%)
CRSP : 62.59 (-0.30%)
CRISPR Therapeutics: A Galaxy's Worth of Deep Value

Wall Street is at max pessimism with this biotech, which might be a big mistake.

CRSP : 62.59 (-0.30%)
VRTX : 332.58 (+2.44%)
3 Disruptors I Love Right Now

These stocks could deliver huge returns as the companies transform the economy.

AMZN : 124.25 (+2.49%)
AYX : 39.53 (+4.27%)
CRSP : 62.59 (-0.30%)
MSFT : 325.26 (+0.58%)
Prediction: These 2 Stocks Could Double In the Next Year

It would be a continuation of solid recent performances.

CRSP : 62.59 (-0.30%)
AXSM : 75.24 (-0.33%)
3 No-Brainer Stocks to Buy for Under $100 Right Now

These stocks might not remain under $100 for too much longer.

CRSP : 62.59 (-0.30%)
NVCR : 45.50 (-6.49%)
PFE : 39.09 (+0.51%)
2 Supercharged Stocks to Buy With $100

These stocks are climbing in the double digits.

VRTX : 332.58 (+2.44%)
CCL : 12.75 (-2.15%)
CUK : 11.31 (-2.33%)
CRSP : 62.59 (-0.30%)
2 Top Trends to Invest $5,000 in Right Now

Renewable energy and gene-editing medical therapies are poised to grow exponentially.

VRTX : 332.58 (+2.44%)
CRSP : 62.59 (-0.30%)
BEP : 31.85 (-0.31%)
Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health

Both stocks are recovering after big losses last year.

VRTX : 332.58 (+2.44%)
CRSP : 62.59 (-0.30%)
TDOC : 24.34 (-2.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

See More

Key Turning Points

3rd Resistance Point 66.55
2nd Resistance Point 65.12
1st Resistance Point 63.86
Last Price 62.59
1st Support Level 61.17
2nd Support Level 59.74
3rd Support Level 58.48

See More

52-Week High 86.95
Fibonacci 61.8% 68.61
Fibonacci 50% 62.94
Last Price 62.59
Fibonacci 38.2% 57.28
52-Week Low 38.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar